{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:26:49Z","timestamp":1786112809046,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000964","name":"Arthritis National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EEQ\/2023\/000779"],"award-info":[{"award-number":["EEQ\/2023\/000779"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104647","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:51:25Z","timestamp":1773942685000},"page":"104647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering virus-like particles for lymph-node targeted cancer immunotherapy: strategies, challenges, and future prospects"],"prefix":"10.1016","volume":"31","author":[{"given":"Hitesh Harsukhbhai","family":"Chandpa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ruchika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shovan","family":"Naskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Saneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-6817","authenticated-orcid":false,"given":"Jairam","family":"Meena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104647_b0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104647_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.drudis.2026.104647_b0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2010.05.019","article-title":"Lympho-geographical concepts in vaccine delivery","volume":"148","author":"Johansen","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104647_b0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41577-019-0243-3","article-title":"Novel vaccine technologies for the 21st century","volume":"20","author":"Mascola","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2026.104647_b0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CJI.0b013e31818f13c4","article-title":"Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes","volume":"32","author":"Cubas","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.drudis.2026.104647_b0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104647_b0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1021\/acsbiomaterials.6b00438","article-title":"Flexible macromolecule versus rigid particle retention in the injected skin and accumulation in draining lymph nodes are differentially influenced by hydrodynamic size","volume":"3","author":"Rohner","year":"2017","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.drudis.2026.104647_b0040","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/14760584.2025.2508517","article-title":"Virus-like particles: a versatile and effective vaccine platform","volume":"24","author":"Bachmann","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.drudis.2026.104647_b0045","first-page":"637","article-title":"Development of a genetically-engineered, candidate polio vaccine employing the self-assembling properties of the tobacco mosaic virus coat protein","volume":"4","author":"Haynes","year":"1986","journal-title":"Biotechnology"},{"key":"10.1016\/j.drudis.2026.104647_b0050","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/304699a0","article-title":"Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides","volume":"304","author":"Emini","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104647_b0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J Immunological Sci"},{"key":"10.1016\/j.drudis.2026.104647_b0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.drudis.2026.104647_b0065","doi-asserted-by":"crossref","first-page":"12963","DOI":"10.3390\/ijms241612963","article-title":"Virus-like particle (VLP) vaccines for cancer immunotherapy","volume":"24","author":"Ruzzi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104647_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124332","article-title":"Surface functionalization of virus-like particles via bioorthogonal click reactions for enhanced cell-specific targeting","volume":"660","author":"Laomeephol","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104647_b0075","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.3390\/molecules27206933","article-title":"Chemical and synthetic biology approaches for cancer vaccine development","volume":"27","author":"Hossain","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104647_b0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.drudis.2026.104647_b0085","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/135965350400900419","article-title":"Activation of dendritic cells and induction of T cell responses by Hpv 16 L1\/E7 chimeric virus-like particles are enhanced by Cpg ODN or sorbitol","volume":"9","author":"Freyschmidt","year":"2004","journal-title":"Antivir Ther"},{"key":"10.1016\/j.drudis.2026.104647_b0090","unstructured":"U.S. Food and Drug Administration. Gardasil. www.fda.gov\/vaccines-blood-biologics\/vaccines\/gardasil. Published 2006. Updated May 14, 2025. Accessed August 12, 2025."},{"key":"10.1016\/j.drudis.2026.104647_b0095","unstructured":"U.S. Food and Drug Administration. Cervarix. www.fda.gov\/vaccines-blood-biologics\/vaccines\/cervarix. Published 2009. Updated October 25, 20Accessed August 12, 2025."},{"key":"10.1016\/j.drudis.2026.104647_b0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbrc.2011.02.122","article-title":"A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae","volume":"407","author":"Sun","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104647_b0105","unstructured":"U.S. Food and Drug Administration. Gardasil 9. www.fda.gov\/vaccines-blood-biologics\/vaccines\/gardasil-9. Published 2014. Updated March 26, 2025. Accessed August 12, 2025."},{"key":"10.1016\/j.drudis.2026.104647_b0110","unstructured":"Strategic Advisory Group of Experts on Immunization (SAGE). Hepatitis E Vaccine: Composition, Safety, Immunogenicity and Efficacy. https:\/\/terrance.who.int\/mediacentre\/data\/sage\/SAGE_Docs_Ppt_Oct2014\/8_session_hepE\/Oct2014_session8_HepE_vax_composition.pdf. Published October, 2014. Accessed August 12, 2025."},{"key":"10.1016\/j.drudis.2026.104647_b0115","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104647_b0120","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nnano.2015.292","article-title":"In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer","volume":"11","author":"Lizotte","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.drudis.2026.104647_b0125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.actbio.2019.09.024","article-title":"Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer","volume":"100","author":"Feng","year":"2019","journal-title":"Acta Biomater"},{"key":"10.1016\/j.drudis.2026.104647_b0130","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3390\/biomedicines10112881","article-title":"Adenovirus-inspired virus-like-particles displaying melanoma tumor antigen specifically target human DC subsets and trigger antigen-specific immune responses","volume":"10","author":"Besson","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2026.104647_b0135","unstructured":"Kirnbauer R. Testing RG1-VLP Vaccine to Prevent HPV-related Cancers. https:\/\/clinicaltrials.gov\/study\/NCT05985681. Published August 2, 2023. Updated September 29, 2025. Accessed August 12, 2025."},{"key":"10.1016\/j.drudis.2026.104647_b0140","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1007\/s13346-024-01521-0","article-title":"Stimuli responsive magnetic-silica-poly lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy","volume":"14","author":"Gupta","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.drudis.2026.104647_b0145","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1080\/17435889.2025.2528591","article-title":"Harnessing multifunctional HBc virus-like particles for safe and effective delivery of melittin in cancer therapy","volume":"20","author":"Wang","year":"2025","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2026.104647_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12257-022-0107-8","article-title":"Virus-like particles as antiviral vaccine: mechanism, design, and application","volume":"28","author":"Zhang","year":"2023","journal-title":"Biotechnol Bioprocess Eng"},{"key":"10.1016\/j.drudis.2026.104647_b0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.drudis.2026.104647_b0160","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.copbio.2013.01.011","article-title":"Reengineering viruses and virus-like particles through chemical functionalization strategies","volume":"24","author":"Smith","year":"2013","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.drudis.2026.104647_b0165","doi-asserted-by":"crossref","first-page":"15046","DOI":"10.1021\/ja044996f","article-title":"A strain-promoted [3\u00a0+\u00a02] azide\u2212alkyne cycloaddition for covalent modification of biomolecules in living systems","volume":"126","author":"Agard","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104647_b0170","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acs.bioconjchem.4c00559","article-title":"Gag HIV-1 virus-like particles and extracellular vesicles functionalization with spike epitopes of SARS-CoV-2 using a copper-free click chemistry approach","volume":"36","author":"Garcia-Trujillo","year":"2025","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.drudis.2026.104647_b0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trechm.2024.12.006","article-title":"Advances in sulfur fluoride exchange for chemical biology","volume":"7","author":"Hansen","year":"2025","journal-title":"Trends Chem"},{"key":"10.1016\/j.drudis.2026.104647_b0180","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1021\/jacs.1c04259","article-title":"A genetically encoded fluorosulfonyloxybenzoyl-l-lysine for expansive covalent bonding of proteins via SuFEx chemistry","volume":"143","author":"Liu","year":"2021","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104647_b0185","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/nano11020318","article-title":"Sulfur(VI) fluoride exchange (SuFEx)-mediated synthesis of the chitosan-PEG conjugate and its supramolecular hydrogels for protein delivery","volume":"11","author":"Jang","year":"2021","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.drudis.2026.104647_b0190","article-title":"Synergistic SuFEx-driven covalent cancer therapy using a HER2\/EGFR bivalent affinity protein drug","volume":"65","author":"Gao","year":"2026","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.drudis.2026.104647_b0195","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1039\/c3cs35459h","article-title":"Photo-induced covalent cross-linking for the analysis of biomolecular interactions","volume":"42","author":"Preston","year":"2013","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104647_b0200","series-title":"Photochemical and Photobiological Reviews","first-page":"105","article-title":"Cross-linking of proteins to nucleic acids by ultraviolet light","author":"Shetlar","year":"1980"},{"key":"10.1016\/j.drudis.2026.104647_b0205","article-title":"Surface crosslinking of virus-like particles increases resistance to proteases, low pH and mechanical stress for mucosal applications","author":"Ali","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2026.104647_b0210","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ae37de","article-title":"Bioprinting collagenase-responsive hydrogel for controlled release of cowpea mosaic virus immunotherapy","volume":"18","author":"Zhao","year":"2026","journal-title":"Biofabrication"},{"key":"10.1016\/j.drudis.2026.104647_b0215","first-page":"112","article-title":"Engineering virus-like particles for antigen and drug delivery","volume":"19","author":"Hill","year":"2018","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.drudis.2026.104647_b0220","first-page":"386","article-title":"Site-specific labeling of proteins using unnatural amino acids","volume":"42","author":"Lee","year":"2019","journal-title":"Mol Cells"},{"key":"10.1016\/j.drudis.2026.104647_b0225","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/biom9070255","article-title":"Site-specific incorporation of unnatural amino acids into Escherichia coli recombinant protein: methodology development and recent achievement","volume":"9","author":"Smolskaya","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104647_b0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.biochem.052308.105824","article-title":"Adding new chemistries to the genetic code","volume":"79","author":"Liu","year":"2010","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.drudis.2026.104647_b0235","first-page":"197","article-title":"Bioorthogonal engineered virus-like nanoparticles for efficient gene therapy","volume":"15","author":"Bao","year":"2023","journal-title":"Nanomicro Lett"},{"key":"10.1016\/j.drudis.2026.104647_b0240","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1073\/pnas.95.4.1800","article-title":"Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor\u2009model","volume":"95","author":"Greenstone","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104647_b0245","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.drudis.2026.104647_b0250","doi-asserted-by":"crossref","first-page":"19234","DOI":"10.1038\/srep19234","article-title":"Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization","volume":"6","author":"Brune","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104647_b0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/srep00005","article-title":"SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure","volume":"1","author":"Walker","year":"2011","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104647_b0260","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s12033-015-9867-0","article-title":"SplitCore technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE","volume":"57","author":"Baltabekova","year":"2015","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.drudis.2026.104647_b0265","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1177\/15353702211010762","article-title":"Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes","volume":"246","author":"Trac","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.drudis.2026.104647_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.nwnano.2025.100128","article-title":"Nanoparticles engineering strategies for lymph-node targeted cancer immunotherapy","volume":"11","author":"Chandpa","year":"2025","journal-title":"Nano Trends"},{"key":"10.1016\/j.drudis.2026.104647_b0275","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104647_b0280","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/pharmaceutics17010070","article-title":"Emerging nanoparticle-based diagnostics and therapeutics for cancer: innovations and challenges","volume":"17","author":"Puttasiddaiah","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104647_b0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omtm.2022.12.003","article-title":"Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth","volume":"28","author":"Besson","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.drudis.2026.104647_b0290","doi-asserted-by":"crossref","first-page":"53682","DOI":"10.1021\/acsami.0c16012","article-title":"Dual-antigen-loaded hepatitis B virus core antigen virus-like particles stimulate efficient immunotherapy against melanoma","volume":"12","author":"Cheng","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2026.104647_b0295","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3390\/cancers12061492","article-title":"Development of a VLP-based vaccine displaying an xCT extracellular domain for the treatment of metastatic breast cancer","volume":"12","author":"Rolih","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104647_b0300","article-title":"A virus-like-particle immunotherapy targeting epitope-specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo","volume":"7","author":"Bolli","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2026.104647_b0305","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1016\/j.vaccine.2019.09.068","article-title":"Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model","volume":"37","author":"Jimenez-Chavez","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2026.104647_b0310","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.imlet.2021.09.002","article-title":"B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer","volume":"239","author":"Jimenez-Chavez","year":"2021","journal-title":"Immunol Lett"},{"key":"10.1016\/j.drudis.2026.104647_b0315","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s44222-022-00016-2","article-title":"Targeted modulation of immune cells and tissues using engineered biomaterials","volume":"1","author":"Yousefpour","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"10.1016\/j.drudis.2026.104647_b0320","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.drudis.2026.104647_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109439","article-title":"A tetravalent nanovaccine that inhibits growth of HPV-associated head and neck carcinoma via dendritic and T cell activation","volume":"27","author":"Josi","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2026.104647_b0330","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.98579.3","article-title":"Engineering PEG10 assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination","volume":"13","author":"Tang","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104647_b0335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00262-025-04023-1","article-title":"In situ treatment with a TLR9 agonist virus-like particle to promote immune responses against oral epithelial dysplasia progression","volume":"74","author":"Xu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.drudis.2026.104647_b0340","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41423-018-0161-5","article-title":"Human dendritic cell-specific ICAM-3-grabbing non-integrin downstream signaling alleviates renal fibrosis via Raf-1 activation in systemic candidiasis","volume":"16","author":"Chen","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2026.104647_b0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142035","article-title":"Head-to-head comparison of soluble vs. Q\u03b2 VLP circumsporozoite protein vaccines reveals selective enhancement of NANP repeat responses","volume":"10","author":"Khan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104647_b0350","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/acsnano.0c03023","article-title":"Glycan-modified virus-like particles evoke T helper type 1-like immune responses","volume":"15","author":"Alam","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2026.104647_b0355","article-title":"Glycan-costumed virus-like particles promote type 1 anti-tumor immunity","author":"Lensch","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2026.104647_b0360","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3390\/cancers13122909","article-title":"Development of a virus-like particle-based anti-HER2 breast cancer vaccine","volume":"13","author":"Hu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104647_b0365","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1021\/acsabm.0c00259","article-title":"Cowpea mosaic virus (CPMV)-based cancer testis antigen NY-ESO-1 vaccine elicits an antigen-specific cytotoxic T cell response","volume":"3","author":"Patel","year":"2020","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.drudis.2026.104647_b0370","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201908743","article-title":"The antitumor efficacy of CpG oligonucleotides is improved by encapsulation in plant virus-like particles","volume":"30","author":"Cai","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.drudis.2026.104647_b0375","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/s41467-025-60239-w","article-title":"A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104647_b0380","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00257-22","article-title":"A system based on novel parainfluenza virus PIV5-L for efficient gene delivery of B-lymphoma cells","volume":"96","author":"Liu","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2026.104647_b0385","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01030-21","article-title":"Paramyxovirus-like particles as protein delivery vehicles","volume":"95","author":"Panthi","year":"2021","journal-title":"J Virol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:23:51Z","timestamp":1785947031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1359644626000528"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104647","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering virus-like particles for lymph-node targeted cancer immunotherapy: strategies, challenges, and future prospects","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104647"}}